依西美坦治疗绝经后乳腺癌临床安全性的Meta分析  

Safety of exemestane in the treatment of breast cancer for postmenopausal women： a meta analysis

作　　者：周冰[1] 孙圣荣[1] 昝晓晨[1] 

机构地区：[1]武汉大学人民医院乳腺甲状腺外科,430060

出　　处：《临床外科杂志》2013年第7期513-515,共3页Journal of Clinical Surgery

摘　　要：目的评价依西美坦对比他莫昔芬治疗绝经后女性乳腺癌的安全性。方法计算机检索PubMed、EMBASE、Cochrane Library、National Technical CNKI、万方数据库等期刊全文数据库；纳入依西美坦对比他莫昔芬治疗绝经后女性乳腺癌的随机对照试验，检索时间从各数据库建库至2013年4月，对符合质量标准的RCT进行Meta分析。结果共纳人8篇随机对照试验文献，Meta分析结果显示，单药或者序贯依西美坦较他莫昔芬有着较高的失眠和关节痛发生率，差异有统计学意义[OR=1．22，95％CI（1．14，1．31），OR：1．31，95％CI（1．22，1．40）]。阴道流血常见于他莫西芬，差异有统计学意义[OR=0．61，95％CI（0．53，0．70）]。结论依西美坦较他莫昔芬有着更高的无病生存率和总体生存率，毒副反应小，发生率低，疗效肯定。Objective To evaluate the safety of exemestane in the treatment of breast cancer for postmenopausal women. Methods Literature search was performed by using PubMed, EMBASE, Coehrane Library, National Technical Information Service, CNKI and Wanfang data from inception to April 2013 for randomized controlled trims（RCT） comparing exemestane and tamoxifen in the treatment of breast cancer for postmenopausal women. The RCT which met the quality standard was enrolled for meta analysis. Re- suits A total of 8 randomized controlled trials were included. The meta analysis showed that,in either sin- gle-drug treatment or sequential treatment, exemestane was associated with a higher incidence of insomnia and joint pain [ OR = 1.22,95 % CI （ 1.14,1.31 ）, OR = 1.31,95 % CI （ 1.22,1.40 ） ]. Vaginal bleeding was more common after treatment of tamoxifen[ OR = 0.61,95% CI （0.53,0.70） ]. Conclusion Com- pared with tamoxifen, exemestane has a higher disease-free survival rate and overall survival rate with low toxicity incidence and certain curative effect.

关 键 词：依西美坦 他莫昔芬 乳腺癌 META分析 

分 类 号：R737.9[医药卫生—肿瘤]